Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ELITE PHARMACEUTICALS INC /NV/

Get SEC filing alerts via email and in your feed for ELITE PHARMACEUTICALS INC /NV/

ELTP

ELITE PHARMACEUTICALS INC /NV/

About ELITE PHARMACEUTICALS INC /NV/

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and manufacturing oral, controlled-release, and generic drugs. It owns a broad portfolio of approved generic products across various therapeutic categories, utilizing proprietary technology and strategic licensing agreements. The company emphasizes product development, manufacturing, and licensing to serve healthcare providers and patients in the U.S. and abroad, with a focus on high-barrier-to-entry generics and abuse-deterrent formulations.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from ELITE PHARMACEUTICALS INC /NV/

1
1
ELITE PHARMACEUTICALS INC /NV/ Elite Pharmaceuticals Reports 120% Revenue Growth and Net Income Turnaround in Latest 10-Q

Via official filing (AI summary) | 4 months ago | 0 comments

2
1
ELITE PHARMACEUTICALS INC /NV/ Elite Pharmaceuticals Reports 92.5% Revenue Growth to $36.3 Million for Quarter Ending September 30, 2025

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
ELITE PHARMACEUTICALS INC /NV/ Elite Pharmaceuticals Reports $40.2 Million Revenue and $5.9 Million Net Loss for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

4
1
ELITE PHARMACEUTICALS INC /NV/ Elite Pharmaceuticals Reports 48% Revenue Growth to $84.0 Million for Fiscal Year Ending March 31, 2025

Via official filing (AI summary) | 12 months ago | 0 comments

5
1
ELITE PHARMACEUTICALS INC /NV/ Elite Pharmaceuticals Reports $14.4M Revenue Decline and $10.9M Net Loss for Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

6
1
ELITE PHARMACEUTICALS INC /NV/ Elite Pharmaceuticals Reports 33% Revenue Growth, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments